Flutamide News and Research

RSS

The efficacy and safety of anti-androgens in the management of hormonal and clinical features of PCOS

The safety and efficacy of anti-androgens in managing polycystic ovary syndrome (PCOS).

1 Sep 2023

Polygenic risk score can predict risk of drug-induced liver injury

Scientists who were working on a way to determine the viability of batches of tiny liver organoids have discovered a testing method that may have far broader implications.

7 Sep 2020

Abiraterone can prolong overall survival and delay severe pain in prostate cancer patients

Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms or so far none at all, and in whom chemotherapy is not yet indicated.

3 Jul 2013

First report of androgen-dependence of exercise on nerve regeneration

A study by researchers from Emory University and Indiana University found that the beneficial effects daily exercise can have on the regeneration of nerves also require androgens such as testosterone in both males and females. It is the first report of both androgen-dependence of exercise on nerve regeneration and of an androgenic effect of exercise in females.

16 Oct 2012

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.

2 Jun 2012

Radiation induces testicular cancer in male fetuses

Male fetuses of mothers that are exposed to radiation during early pregnancy may have an increased chance of developing testicular cancer, according to a study in mice at The University of Texas MD Anderson Cancer Center.

14 Feb 2012

Mix of endocrine disrupters a dangerous cocktail

Endocrine-disrupting chemicals, which are harmless individually in small doses, can together be a dangerous cocktail.

20 Feb 2008

Benefits of short-term hormonal therapy for men receiving radiation therapy for prostate cancer far outweigh the risks

Researchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight years - especially the development of bone metastases - and increased survival in older men with potentially aggressive prostate cancer.

4 Jan 2008

Monitoring anemia provides clues to prostate cancer treatment response

Researchers from the Oregon Health & Science University Cancer Institute and Southwest Oncology Group have identified a new method of determining how men with advanced prostate cancer will respond to treatment.

1 Jun 2006

Cancer vaccine combined with hormone-deprivation therapy can help patients with recurrence of prostate cancer

A new study finds that a cancer vaccine combined with hormone-deprivation therapy can help patients with recurrence of prostate cancer. The results of this clinical trial, led by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, appear in the August 2005 issue of the Journal of Urology.

26 Jul 2005

Australian-New Zealand hormone therapy trial good news for prostate cancer patients

Results of a major trial of hormone therapy on men with locally advanced prostate cancer announced today were a significant development and would be welcomed by patients and oncologists world-wide, according to The Cancer Council Australia.

23 May 2005

Phase II trials of the first second-generation antisense cancer drug to be used in patients soon to be underway

Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.

28 Sep 2004

The April 2004 issue of Otolaryngology focuses on head and neck surgery

The efficacy of a new cancer-fighting virus is tested in the study, “Treatment of Solid Sarcomas in Immunocompetent Mice with Novel Oncolytic Herpes Simplex Viruses.” A team of multi-disciplinary Japanese researchers found that a weakened version of herpes simplex virus (HSV) effectively eradicated neck and flank tumors in mice.

23 Apr 2004